

Ref : JPL/CS/1701/2021.

Date : 23rd May, 2021.

To
BSE Ltd.,
Phiroze Jeejeebhoy Towers,
Dalal Street, Fort,
Mumbai - 400 001.

Script Code : **524731**Reg.: **Intimation under Regulation 29(1) and 30 of SEBI (Listing Obligations and Disclosure Requirement) Regulations, 2015.**Sub. : **Board Meeting.**

Dear Sir,

Kindly take note that with reference to the captioned regulation a Meeting of the Board of Directors of the Company is scheduled to be held on Wednesday, 02nd June, 2021, at the Registered Office of the Company, inter alia, to take on record the audited financial results for the quarter and financial year ended on 31st March 2021 and to consider recommendation of Dividend, if any.

Kindly also take note that the Board will also consider:

1. To consider a proposal to acquire a land in the state of Gujarat, to set up a modern pharmaceutical formulations manufacturing unit and authorize Director to take necessary steps in respect of the same.
2. To consider a proposal to begin on pilot scale to sell certain Healthcare products via digital marketing.

With reference to our letter no. JPL/CS/1690/2021 dated 31st March, 2020, submitted with the Exchange, on the same day, the notional trading window is closed from 1st April, 2021 up to 48 hours after the completion of Board Meeting scheduled on 2nd June, 2021.

Kindly take on record the above.

Thanking you,

Yours faithfully,
For Jenburkt Pharmaceuticals Ltd.,

Ashish
Rasiklal Shah



(ASHISH R. SHAH)
Company Secretary and Compliance Officer